TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12481675
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (10 g) with metoclopramide (10 mg)
Study: 20350147
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg once daily
Study: 1898891
Drug: Low-dose human
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose human menopausal gonadotropin (hMG)
Study: 17265577
Drug: Simplified version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified version of the HIV vaccine process
Study: 15576836
Drug: 5.6 g
Normalized name: aspirin 15.6 GM Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.6 g of phosphatidylinositol (PI) with food
Study: 7486464
Drug: 7-valent pneumococcal-conjugate
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal-conjugate vaccine
Study: 7486464
Drug: HIB-conjugate vaccine
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HIB-conjugate vaccine
Study: 323297
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium phosphate (40, 80, or 160 mg)
Study: 20805299
Drug: Saracatinib 175
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 175 mg once daily
Study: 22178855
Drug: injectable trace
Normalized name: Trace metal Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: injectable trace mineral supplement (ITM; n = 42; 7 mL subcutaneous; MultiMin, Fort Collins, CO)
Study: 7781259
Drug: All four
Normalized name: Jackson's The Original All Fours
Approvals — FDA: no, EMA: no, PMDA: no
Description: All four treatments (torsemide and furosemide in both oral and intravenous forms)
Study: 30950637
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment after initial treatment (MSM or BPT)
Study: 23842127
Drug: sustained HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained HIV-1 RNA suppression below 400 copies/ml
Study: 7808491
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and ticlopidine
Study: 12454840
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg/day
Study: 8659784
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ED95 dose of 100 microg/kg mivacurium)
Study: 22187804
Drug: Oral amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amino acid supplementation
Study: 20110014
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 225 mg tablet (study C)
Study: 20110014
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 150 mg + 75 mg capsules (study D)
Study: 26314902
Drug: Gabapentin 800
Normalized name: gabapentin 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 800 mg (at night and 2 hours prior to induction)
Study: 8658075
Drug: Powdered acidified
Normalized name: Acidifiers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered acidified full fat cow's milk fortified with 15 mg of iron as ferrous sulfate
Study: 25133963
Drug: celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: celecoxib 200 mg (qd)
Study: 16266300
Drug: End-point rectal
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End-point rectal rewarming temperature at 37.0 degrees C (Group 2)
Study: 19628959
Drug: Rogerian supportive
Normalized name: geranium oil, Algerian type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogerian supportive therapy (RST)
Study: 15041600
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg IV
Study: 9690059
Drug: Inpatient structured
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient structured diabetes treatment and teaching programme (DTTP)
Study: 30784669
Drug: Full post-PCI
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full post-PCI bivalirudin infusion (1.75 mg/kg/h for ≤4 h)
Study: 20042452
Drug: Seawater gel
Normalized name: Sodium Chloride 2600 mg in 100 mL NASAL SPRAY [NasalAsalt All-Natural Seawater]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seawater gel
Study: 7936855
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D and phosphate therapy added to Vitamin D alone
Study: 22205670
Drug: Sodium chlorate
Normalized name: Sodium Chlorate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chlorate 150 mg/kg BW
Study: 21636711
Drug: Postoperative systemic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative systemic multiagent chemotherapy and intraventricular methotrexate (3 cycles, with possible additional 2 cycles if in complete remission)
Study: 7955291
Drug: HeartMate 1000
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HeartMate 1000 IP LVAD with no anticoagulants
Study: 7955291
Drug: HeartMate 1000
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HeartMate 1000 IP LVAD with heparin
Study: 12209041
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg q.d.
Study: 26264399
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (daily)
Study: 21059395
Drug: pCEsa1 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pCEsa1 DNA vaccine
Study: 8798310
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (LLETZ and RCDF)
Study: 11717654
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous combined hormone replacement therapy (0.3 mg conjugated equine estrogens and 2.5 mg medroxyprogesterone acetate plus 1000 mg calcium per day)
Study: 26006264
Drug: Active Computerized
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Computerized Control (CC)
Study: 12685057
Drug: Novel antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel antithrombotic agents
Study: 10697082
Drug: Antibiotic-impregnated bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic-impregnated bone grafting
Study: 8123269
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine with 0.1 mEq/ml of sodium bicarbonate (NaHCO3)
Study: 21419684
Drug: Post-discharge pharmaceutical
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-discharge pharmaceutical care programme (verbal and written information about treatment)
Study: 20923790
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO₄)
Study: 22512898
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg OROS-MPH
Study: 22512898
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg MPH ER-C
Study: 16130428
Drug: Bronchodilators (general)
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators (general)
Study: 23061633
Drug: High oleic
Normalized name: High Oleic Sunflower Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High oleic safflower oil (HOSF) 2.5 ml p/d for 8 weeks
Study: 9291856
Drug: Auranofin 3
Normalized name: auranofin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auranofin 3 mg b.i.d.
Study: 16368820
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol IV injection
Study: 16698176
Drug: Oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 5 mg t.i.d.
Study: 28877711
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles 10 μg, 50 μg, or 100 μg
Study: 28877711
Drug: Carbon nanoparticles
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticles 100 μg
Study: 17259789
Drug: T3-Ibsa oral
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T3-Ibsa oral solution
Study: 16533223
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy
Study: 9690953
Drug: (+/-)-sotalol 240
Normalized name: sotalol hydrochloride 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/-)-sotalol 240 mg
Study: 10073841
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin K1
Study: 35075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving Totamine starting on the day of surgery, providing 1200 calories and 12.4 g of nitrogen per day.
Study: 31575825
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg·kg‐1
Study: 17426086
Drug: Physiological testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiological testosterone administration, 300 mug daily
Study: 12167274
Drug: Enfuvirtide (T-20)
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide (T-20) subcutaneous injection (50 or 100 mg twice daily)
Study: 15752403
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of thermal indicator into the right atrium
Study: 14998068
Drug: Rizatriptan 10
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10 mg
Study: 7532930
Drug: Balloon occluded
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon occluded arterial infusion (BOAI) treatment
Study: 16810076
Drug: Fenofibrate and
Normalized name: Fenofibrate and rosuvastatin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate and control groups (baseline CRP >or=3 mg/dL)
Study: 23394513
Drug: Fexofenadine at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine at 180 mg
Study: 7195414
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (1 g four times a day) for 3 days
Study: 22027845
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg/day
Study: 9355077
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil therapy
Study: 10874258
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enoxaparin (1 mg/kg) and unfractionated heparin (12,500 IU)
Study: 28805667
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of standardized ginger extract per day
Study: 11505809
Drug: Combined antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibiotic and/or antiphlogistic regimen followed by L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A1/B1)
Study: 26237936
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active and control treatments
Study: 24614995
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 50,000 IU weekly
Study: 31663816
Drug: Non-anabolic androgen
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anabolic androgen steroids (AS) users
Study: 22353811
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and thalidomide
Study: 28947039
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 100 μg combined with vilanterol 25 μg (FF/VI)
Study: 22885164
Drug: Rituximab chemotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab chemotherapy induction
Study: 27760081
Drug: Oxybutynin 15
Normalized name: oxyBUTYnin 15 mg/24 hr oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 15 mg once daily
Study: 8625679
Drug: Oral Appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Appliance (OA)
Study: 9990415
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel
Study: 22206079
Drug: Tretinoin 0.025%
Normalized name: TRETINOIN 0.025% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025% cream
Study: 28486381
Drug: Concurrent Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Foley and oxytocin
Study: 12792359
Drug: Group counseling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counseling plus individual drug counseling (IDC)
Study: 20395096
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (5 g/day for 8 weeks)
Study: 8669567
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg
Study: 3730529
Drug: Promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 25 mg
Study: 26400368
Drug: Nintedanib 150
Normalized name: nintedanib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 150 mg twice daily
Study: 22448810
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg plus mosapride 5 mg
Study: 16953457
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg alone
Study: 27762628
Drug: First 100
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 100 shockwaves at 40% power, then 80% power until the end of treatment
Study: 27762628
Drug: First 100
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First 100 shocks at 80% power, followed by a 3‐minute pause, then 80% power until the end of treatment
Study: 21067018
Drug: Tablet Ciprofloxacin
Normalized name: ciprofloxacin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Ciprofloxacin 500 mg
Study: 21067018
Drug: Injection Ceftriaxone
Normalized name: ceftriaxone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Ceftriaxone 500 mg
Study: 17984842
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg FTY720 (Group 1)
Study: 17984842
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg FTY720 (Group 2)
Study: 19729344
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg glatiramer acetate
Study: 19544315
Drug: Fluoxetine or
Normalized name: fluoxetine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine or Nortriptyline
Study: 14638885
Drug: Pyridostigmine 60
Normalized name: pyRIDostigmine 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 60 mg four times a day for 14 weeks
Study: 3102414
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron therapy
Study: 8818502
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of locoregional recurrence
Study: 22089991
Drug: Sonographic image-guided
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sonographic image-guided injection
Study: 16831439
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus N-acetyl cysteine (50 mg twice per day and 1200 mg/d for 5 days)
Study: 19608026
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day
Study: 9579625
Drug: 1-stage full-mouth
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-stage full-mouth disinfection (scaling and root planing of all pockets within 24 hours, application of chlorhexidine to all intra-oral niches, chlorhexidine mouth rinsing for 2 months)
Study: 9579625
Drug: Fractionated periodontal
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated periodontal therapy (consecutive root planings per quadrant at a 1 to 2 week interval)
Study: 9579625
Drug: 1-stage full-mouth
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-stage full-mouth disinfection and fractionated periodontal therapy
Study: 2764538
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment with enoxacin (200 mg twice a day)
Study: 23128421
Drug: Rapid Sequence
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Sequence Induction (RSI) with thiopental 2‐3 mg/kg and remifentanil 1 mcg/kg
Study: 17000820
Drug: Aspirin gargle
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin gargle (350 mg)
Study: 29462230
Drug: Oxymetazoline cream
Normalized name: oxymetazoline Topical Cream
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxymetazoline cream 1.5% applied once daily
Study: 19861283
Drug: Defibrase therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrase therapy (intravenous infusion at doses of 15, 10, and 5 U based on plasma FIB levels)
Study: 2725277
Drug: Trilostane 240
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilostane 240 mg/d (Trilo 240)
Study: 25876706
Drug: Oral OKT3
Normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OKT3 1.0 mg/day (Group C)
Study: 2574262
Drug: Intramuscular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chloroquine (3.5 mg base/kg every 6 h)
Study: 8095573
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether
Study: 25407583
Drug: Face-to-face administered
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face administered cognitive behavioral therapy (FtF‐CBT)
Study: 25003151
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (5 ng · mL(‐1))
Study: 19100067
Drug: Autoantibodies against
Normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autoantibodies against beta(1) adrenergic receptor
Study: 19100067
Drug: Autoantibodies against
Normalized name: Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s
DrugBank: Sutimlimab (DB14996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autoantibodies against M(2) adrenergic receptor
Study: 30977312
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) guided antibiotic discontinuation
Study: 28007137
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (ADT)
Study: 21045074
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal nicotine (low dose)
Study: 17075823
Drug: Ineligible patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineligible patients (not receiving TNF inhibitors)
Study: 12532160
Drug: MCT diet
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT diet (67% of treatment fat as MCT oil, 49% octanoate, 50% decanoate)
Study: 20057309
Drug: Continuous antiretroviral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous antiretroviral therapy (Viral Suppression group)
Study: 31076187
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg citalopram